logo
Volume 7, Issue 2 (3-2020)                   jbrms 2020, 7(2): 7-12 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hemati S, Shams M, Rahmatian A, Nourmohammadi H, Abdoli A, Maleki F, et al . The patterns of aminoglycoside and fluoroquinolones resistance among uropathogenic Escherichia coli isolates. jbrms 2020; 7 (2) :7-12
URL: http://jbrms.medilam.ac.ir/article-1-483-en.html
Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran
Abstract:   (2357 Views)
Introduction: In the study we sought to determine the patterns of regional antibiotic resistances among uropathogenic Escherichia coli (UPEC) isolates. Our finding could be useful for better recognition of regional antibiotic resistances and scheduling a program to control this condition.
Materials and methods: In the study, 270 nonduplicate UPEC isolates were examined from urine samples of outpatients with urinary tract infections (UTIs). All isolates were identified by gram staining and standard conventional biochemical tests. Antimicrobial susceptibility test was performed by disk diffusion (Kirby–Bauer) method. The commercial antibiotics disks (PADTAN TEB Co., Iran) were applied in the study, included amikacin (30 μg), gentamycin (10 μg), ciprofloxacin (5 μg), and nalidixic acid (30 μg).
Results: Most of the patients were female (221, 81.9%). The highest resistance was observed for nalidixic acid (56%), followed by ciprofloxacin 39.64%. In contrast, the lowest resistance was seen for amikacin (3.90%) and gentamicin (10.04%). Moreover, 19.62% of the isolates were multidrug-resistant (MDR).
Conclusion: Amikacin and gentamicin could be chosen as first line antibiotics in treatment of UTIs. Continuous monitoring studies recommended for acquire a suitable regional antibiotic resistance pattern.
Full-Text [PDF 464 kb]   (1005 Downloads)    
Type of Study: Research | Subject: Microbiology
Received: 2020/02/11 | Accepted: 2020/05/26 | Published: 2020/03/1

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.